← All trials
NCT07044544
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2025
- Primary completion
- Dec 31, 2026
- Completion date
- Jan 31, 2027
- First posted
- Jul 1, 2025
- Last posted
- Sep 10, 2025
- Enrollment
- 20
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Alabama, BirminghamLead sponsor
- University of Alabama, BirminghamSponsor investigator
- University of Alabama, BirminghamOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.